Document Detail


Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity.
MedLine Citation:
PMID:  7668286     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The polymorphic arylamine N-acetyltransferase (NAT2; EC 2.3.1.5) is supposed to be a susceptibility factor for several drug side effects and certain malignancies. A group of 844 unrelated German subjects was genotyped for their acetylation type, and 563 of them were also phenotyped. Seven mutations of the NAT2 gene were evaluated by allele-specific PCR (mutation 341C to T) and PCR-RFLP for mutations at nt positions 191, 282, 481, 590, 803, and 857. From the mutation pattern eight different alleles, including the wild type coding for rapid acetylation and seven alleles coding for slow phenotype, were determined. Four hundred ninety-seven subjects had a genotype of slow acetylation (58.9%; 95% confidence limits 55.5%-62.2%). Phenotypic acetylation capacity was expressed as the ratio of 5-acetylamino-6-formylamino-3-methyluracil and 1-methylxanthine in urine after caffeine intake. Some 6.7% of the cases deviated in genotype and phenotype, but sequencing DNA of these probands revealed no new mutations. Furthermore, linkage pattern of the mutations was always confirmed, as tested in 533 subjects. In vivo acetylation capacity of homozygous wild-type subjects (NAT2*4/*4) was significantly higher than in heterozygous genotypes (P = .001). All mutant alleles showed low in vivo acetylation capacities, including the previously not-yet-defined alleles *5A, *5C, and *13. Moreover, distinct slow genotypes differed significantly among each other, as reflected in lower acetylation capacity of *6A, *7B, and *13 alleles than the group of *5 alleles. The study demonstrated differential phenotypic activity of various NAT2 genes and gives a solid basis for clinical and molecular-epidemiological investigations.
Authors:
I Cascorbi; N Drakoulis; J Brockmöller; A Maurer; K Sperling; I Roots
Related Documents :
15349706 - Fatal intoxication cases: cytochrome p450 2d6 and 2c19 genotype distributions.
10022246 - Recent advances in understanding the molecular basis of polymorphisms in genes encoding...
15801936 - Pharmacogenetic profiling across the irinotecan pathway in asian patients with cancer.
9663176 - Influence of genetic admixture on polymorphisms of drug-metabolizing enzymes: analyses ...
10626826 - Genetic and dietary factors in idiopathic calcium nephrolithiasis. what do we have, wha...
12165926 - Contributions of 18 additional dna sequence variations in the gene encoding apolipoprot...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of human genetics     Volume:  57     ISSN:  0002-9297     ISO Abbreviation:  Am. J. Hum. Genet.     Publication Date:  1995 Sep 
Date Detail:
Created Date:  1995-10-12     Completed Date:  1995-10-12     Revised Date:  2010-09-08    
Medline Journal Info:
Nlm Unique ID:  0370475     Medline TA:  Am J Hum Genet     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  581-92     Citation Subset:  IM    
Affiliation:
Institute of Clinical Pharmacology, University Clinic Charité, Humboldt University of Berlin, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alleles
Arylamine N-Acetyltransferase / genetics*
Base Sequence
European Continental Ancestry Group / genetics
Genotype
Humans
Linkage (Genetics)*
Molecular Sequence Data
Mutation
Phenotype
Polymerase Chain Reaction
Chemical
Reg. No./Substance:
EC 2.3.1.5/Arylamine N-Acetyltransferase; EC 2.3.1.5/NAT2 protein, human
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The molecular basis of canavan (aspartoacylase deficiency) disease in European non-Jewish patients.
Next Document:  Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disea...